The Health Sector Coordinating Council, through its Cybersecurity Working Group, published a guide to help healthcare organizations manage cybersecurity risks in AI-driven supply chains. It focuses on gaps in vendor visibility and disclosure, where incomplete inventories and unreported AI-specific risks, such as data leakage and adversarial threats, complicate oversight. The guide promotes proactive due diligence, continuous risk profiling, and stronger contractual transparency, equipping organizations to identify hidden dependencies, manage third-party risks, and align AI (artificial intelligence) technologies with safety, privacy, and resilience priorities.
Titled ‘Health Industry Third-Party AI Risk and Supply Chain Transparency Guide,’ the HSCC document addresses the growing gaps in discovery and disclosure processes that make AI supply chain risk so difficult to manage. Many healthcare organizations operate with incomplete or outdated vendor inventories, while AI-specific cybersecurity risks, such as synthetic data misuse, training data leakage, and adversarial inference, go unreported by vendors. To counter this, the guide promotes proactive due diligence, dynamic risk profiling, and contractual transparency. It equips risk managers, compliance teams, and procurement officers with scalable tools to surface hidden dependencies, identify cascading failure points, and align third-party AI vendors and products with mission-critical safety, privacy, and resilience goals.
The document recognizes that the healthcare sector’s accelerating AI adoption has expanded its dependence on third-party tools and services, introducing complex cybersecurity challenges that traditional risk management models cannot adequately address.
From AI-driven clinical decision support systems embedded in EHRs (electronic health records) to remote monitoring devices and administrative automation, healthcare organizations face a range of escalating risks. Visibility into AI components is often limited due to layered supply chains that include subcontractors, offshore development, and open-source assets, increasing systemic exposure and complicating incident response.
Organizations also struggle to verify vendor security postures, data governance practices, and model integrity. In many cases, vendors shift risk onto healthcare organizations through one-sided contract terms or by refusing to sign HIPAA Business Associate Agreements. These challenges are compounded by incomplete vendor inventories and the lack of disclosure around AI-specific cybersecurity risks such as synthetic data misuse, training data leakage, and adversarial inference.
At the same time, rapid evolution of AI infrastructure, algorithms, and models introduces additional complexity, creating steep learning curves, continuously emerging risks, and a significantly expanded attack surface.
“Managing third-party AI risk requires a structured, lifecycle-based approach that recognizes the unique characteristics of artificial intelligence systems,” the HSCC guide noted. “Unlike traditional software, AI systems introduce dynamic risks through model drift, training data dependencies, algorithmic bias, and complex supply chain relationships that may span multiple vendors, open-source components, and cloud service providers. This process establishes a shared responsibility model between HCOs and third-party AI vendors, ensuring transparent management of AI-specific risks throughout the entire technology lifecycle.”
The guide aligns with the Health Industry Cybersecurity Practices for Supply Chain Risk Management (HIC-SCRiM) as a baseline and incorporates AI-specific controls. This process should be considered as an enhancement to, not a replacement of, a vendor risk process.
The HSCC guide detailed that effective AI risk management begins with governance policy development that clearly defines accountability, data handling practices, ethical considerations, security controls, and incident reporting requirements. This foundation must be reinforced by procurement processes that require clear use case justification and incorporate enhanced Governance, Risk, and Compliance (GRC) assessments with AI-specific criteria such as data lineage, bias mitigation, security safeguards, and transparency.
Organizations also need robust contract and legal protections, including defined terms for data ownership, restrictions on AI training, management of product updates, performance expectations, and liability provisions, along with strengthened Business Associate Agreement clauses to address AI-specific HIPAA compliance obligations. At the same time, maintaining visibility is critical, which requires systematic inventory and asset management approaches to identify existing AI systems and establish continuous tracking of AI tools, applications, and embedded capabilities.
Quality assurance must be treated as an ongoing discipline through structured verification and validation frameworks for third-party AI solutions, supported by vendor testing documentation, validation in staging environments, and mandatory re-validation following updates. These controls should be complemented by response and recovery planning that integrates incident response coordination with AI vendors, enables model rollback procedures, and ensures resilience under failure conditions.
Finally, end-of-life management processes are essential to govern AI system transitions, ensuring secure data migration and the proper decommissioning of systems without introducing residual risk.
Healthcare organizations should establish AI governance structures aligned with their size and complexity, with clear accountability for oversight, security attestations, risk categorization, approval processes, and training requirements. They should implement shared responsibility models with vendors by enforcing contractual transparency, requiring advance notification of changes, and conducting joint validation activities.
Procurement workflows need to be strengthened to identify the presence of AI early in the acquisition process and ensure comprehensive vetting before deployment. Organizations should also actively manage the full AI lifecycle, from initial assessment through to end-of-life, with close attention to update management and configuration validation.
Greater vendor transparency is essential, particularly around model training data, potential biases, and system dependencies, based on the specific use case, risk level, and business impact. In parallel, organizations should work to surface hidden dependencies by maintaining active inventories and using dynamic risk profiling alongside scalable due diligence tools.
The ‘Phase 0: AI Use Case Justification & Strategic Assessment’ serves as a critical gatekeeping step before organizations commit to AI vendor evaluations. It requires healthcare organizations to rigorously assess whether AI is truly the right solution by documenting the specific problem, evaluating non-AI alternatives, analyzing ROI and total cost of ownership, and classifying the AI system by safety impact, ranging from Low (e.g., email autocomplete) to Critical (e.g., autonomous diagnostic AI).
Key stakeholders across privacy, security, legal, and compliance are identified early, and governance requirements are established based on risk level. The phase also examines data sensitivity, regulatory classification, model transparency, and where data and models are hosted.
The ultimate goal is to ensure AI is adopted only when there is clear strategic alignment, demonstrable value, and acceptable risk, not for innovation’s sake. By completing this phase, organizations produce a Use Case Justification Document, an Initial Risk Classification, a Stakeholder Identification Matrix, and a Business Case with ROI/TCO analysis. This disciplined foundation prevents costly mistakes, streamlines subsequent vendor evaluations, and builds organizational consensus on goals, risk tolerance, and accountability before any resources are committed.
In the ‘Phase 1: Vendor Evaluation and Due Diligence’ stage, healthcare organizations determine which AI vendors can be trusted with patient data, clinical workflows, and operations. Unlike standard software evaluations, AI vendor assessment demands deeper scrutiny, covering training data provenance, algorithmic bias mitigation, model transparency, external AI dependencies, and responsible AI governance.
A key challenge is that this evaluation must apply not only to new vendors in active procurement, but also retroactively to existing vendors already deployed, as many organizations discover through asset inventory that AI capabilities have proliferated without formal oversight. To manage this, organizations should implement tiered assessment frameworks including baseline questions for all AI vendors, enhanced assessments for Medium/High-impact systems, and comprehensive evaluation for Critical-impact AI, executed through cross-functional collaboration across procurement, security, privacy, compliance, legal, and clinical leadership.
The assessment spans both standard third-party risk evaluation (financial stability, cybersecurity certifications, data residency, contractual terms) and AI-specific governance, risk, and compliance review. The latter covers data lineage and bias mitigation, model transparency and explainability, AI-specific security risks (such as prompt injection, data poisoning, and model theft), regulatory compliance (FDA, HIPAA, EU AI Act), third-party supply chain dependencies, operational readiness, and ethical AI practices.
The phase concludes with a completed GRC assessment, a Security Risk Assessment Report, a vendor scorecard with risk ratings, and a gap analysis, producing a recommendation to approve, conditionally approve, or reject the vendor. The core takeaway is that AI vendor evaluation requires both traditional IT security assessment and specialized AI risk evaluation, scaled to the organization’s size and the risk profile of the specific solution.
For ‘Phase 2: Contract Negotiation & Legal Protections,’ the HSCC guide addresses inadequacy of standard software licensing agreements and BAAs for AI systems in healthcare. Unlike conventional software, AI systems evolve through model updates, drift over time, and exhibit unpredictable behaviors, making specialized contractual protections essential. Effective AI contracting must establish a shared responsibility framework that defines accountability for governance, risk, security, and compliance; enforces transparency obligations around model architecture, training data, and dependencies; and provides audit rights, update approval processes, and termination protections.
For any AI system processing PHI, BAAs require AI-specific amendments covering model training restrictions, data minimization, breach notification timelines, and security safeguards aligned with HIPAA. Contract management must also extend beyond execution, organizations need to continuously monitor vendor compliance, track renewals, document performance issues, and update terms as technology and regulations evolve.
The AI-specific contract clauses that organizations must negotiate span a broad range of concerns: data ownership and restrictions on vendors using organizational data to train models without explicit consent; security and compliance requirements tied to GRC assessment findings; change management processes for model updates with advance notification and rollback rights; model performance and bias monitoring commitments; incident response obligations with defined timelines; data return and secure destruction at contract end; third-party supply chain transparency; regulatory compliance and liability allocation for AI-generated errors; and end-of-life transition support with a minimum 12–18 months advance notice.
The phase concludes with a Master Services Agreement containing AI-specific clauses, an AI-tailored BAA or addendum, a Service Level Agreement, and a Data Processing Agreement where applicable. The core takeaway is that standard vendor contracts are insufficient, thus organizations must negotiate protections specifically addressing AI’s unique risks around data use, model behavior, explainability, bias, and shared accountability.
Under ‘Phase 3: Implementation, Integration & Training,’ the HSCC guide covers critical transition to production deployment. Unlike traditional software, AI implementations require additional validation of model performance, bias mitigation, clinical accuracy, and fail-safe mechanisms, since AI systems can behave unpredictably with real-world data and create unintended consequences when integrated with existing clinical systems.
A core requirement before go-live is AI-specific threat modeling that goes beyond traditional static code analysis to address behavioral vulnerabilities such as prompt injection, data poisoning, model manipulation, and excessive agency. Organizations must assess their full healthcare attack surface across EHR integrations, clinical decision support, patient-facing chatbots, and ambient documentation and evaluate the solution against the OWASP Top 10 for LLM Applications.
It added that where agentic AI is involved, additional threat modeling must treat AI agents as a new category of insider, with documented identities, constrained permissions, and behavioral baselines for anomaly detection.
Technical integration must proceed through sandbox testing, security validation, AI-specific security testing, and clinical validation before production rollout, verifying that threat model controls are functioning, encryption and access controls are in place, human override capabilities work correctly, and AI outputs are treated as untrusted until validated.
Alongside this, organizations must conduct or update a Privacy Impact Assessment, address patient consent and disclosure requirements, and establish an AI-specific incident response playbook with graduated escalation procedures and tabletop exercises completed before go-live. Equally critical is role-specific user training, covering AI limitations, error recognition, override procedures, and AI-specific security awareness, supported by competency assessments before granting production access.
The phase concludes with a phased production rollout under enhanced monitoring, with all systems, data flows, AI agent identities, and risk documentation registered in the organizational asset inventory. The key takeaway is that traditional application security and standard software deployment practices are insufficient; AI demands continuous behavioral monitoring, rigorous pre-deployment validation, and a security program that evolves alongside AI capabilities and threats.
For ‘Phase 4: Ongoing Monitoring & Performance Management,’ the HSCC guide provides the longest and most resource-intensive phase of the AI lifecycle, spanning from deployment through end-of-life. Unlike traditional software, AI systems demand continuous monitoring because models drift as input data changes, performance degrades gradually, and frequent vendor updates involving model retraining introduce risks that standard change management cannot address, including security configurations resetting to defaults, emerging bias across patient populations, and evolving AI-specific threats like prompt injection.
Effective monitoring requires sustainable, risk-based processes with automation, including dashboards tracking performance indicators, alerting systems flagging anomalies, and drift detection tools, while maintaining human oversight and clear escalation paths. Key monitoring activities include tracking model accuracy, false positive/negative rates, user override patterns, and clinical outcome correlation; detecting model drift and concept drift against defined thresholds; and monitoring AI performance across demographic subgroups to identify discriminatory outcomes or disparate impact.
On the security and compliance side, organizations must continuously validate access controls, scan for AI-specific vulnerabilities, audit BAA compliance and PHI handling, and monitor for attack patterns such as prompt injection and adversarial inputs. Vendor update and patch management requires a structured process, involving receiving and assessing update notifications, deploying to a sandbox environment first, validating that security settings were not reset, and conducting post-deployment monitoring before full production approval.
Vendor performance must be tracked against SLA commitments with regular check-ins and escalation of persistent issues through governance channels. Periodic reassessments, typically annual or at contract renewal, should revalidate AI system performance and safety, update risk classifications, and reassess vendor security posture. The core takeaway is that AI systems require significantly more intensive ongoing monitoring than traditional software, and organizations must build sustainable, automated monitoring programs with clear escalation paths to manage model drift, frequent updates, and continuously evolving risks.
The Phase 5: Incident Response & Recovery acknowledges that AI incidents should be anticipated even with rigorous controls, and that traditional IT incident response procedures are insufficient to address them. AI failures are uniquely challenging — they can be subtle, manifest as gradual degradation rather than catastrophic failure, and involve corrupted training data, accumulated model drift, or emergent behaviors that cannot be easily reversed.
Organizations must prepare for a range of AI-specific incident scenarios including security breaches affecting training data, model performance failures, bias events producing discriminatory outputs, adversarial attacks, and model hallucinations generating erroneous clinical recommendations. Effective response requires pre-established frameworks covering incident classification by severity, vendor coordination protocols with contractually defined notification timeframes, immediate containment actions (such as isolating affected systems or suspending AI operations), forensic investigation, and coordinated remediation with vendors engaged throughout rather than treated as peripheral parties.
Recovery goes beyond restoring systems to validating that AI model performance, data integrity, and security controls have been fully rehabilitated before returning to normal operations with rollback to previously validated model versions where necessary and abbreviated revalidation conducted in the current environment. Post-incident activities must include root cause analysis with vendor participation, regulatory reporting where required (FDA, HHS OCR, state agencies), corrective and preventive action (CAPA) plans, and updates to incident response procedures based on lessons learned.
Organizations are also advised to require vendors to conduct periodic reassessments following model updates, retraining events, or emerging threat intelligence. Critically, vendor dependencies for AI incidents are higher than for traditional software, recovery time objectives may be longer due to revalidation requirements, and bias or model failure events may require distinct regulatory reporting and communication strategies separate from standard security incident procedures. Regular tabletop exercises simulating AI-specific scenarios, including vendor participation, are essential to maintaining preparedness.
In ‘Phase 6: End-of-Life & Transition Management,’ the HSCC guide addresses the unique challenges AI systems present when they reach end-of-life, whether through planned vendor discontinuation, technological obsolescence, or unplanned events such as vendor failure or third-party model deprecation. Unlike traditional software with predictable support cycles, AI systems face distinct EOL risks: models may depend on external services deprecated without the primary vendor’s control, organizational data may be embedded in model weights requiring specialized destruction beyond standard data deletion, and replacing one AI model with another may not maintain equivalent clinical performance without comprehensive revalidation.
Proactive EOL planning must begin during initial contracting by securing vendor notification requirements (minimum 12–18 months advance notice), data extraction rights, and secure destruction procedures. Upon receiving an EOL notification, organizations must assess operational, clinical, cybersecurity, and regulatory impact; decide whether to replace or discontinue the system; conduct an expedited vendor evaluation if replacement is needed; and plan a migration timeline that minimizes disruption to clinical operations.
Data management is a critical component of EOL, requiring a full inventory and classification of associated data, including training datasets, audit trails, clinical decision documentation, and user interaction logs, followed by extraction in interoperable formats, migration or archival per retention policies, and vendor-certified secure destruction of all organizational data from production systems, backups, training datasets, and AI model weights per NIST 800-88 or equivalent standards. If a replacement system is onboarded, organizations must follow implementation procedures adapted for urgency, conduct equivalence testing comparing legacy and replacement AI outputs, and retrain users with emphasis on workflow changes.
Throughout, regulatory obligations must be maintained, including FDA notifications if a medical device is being replaced, HIPAA compliance, and patient communication if EOL affects their care or data. The key takeaway is that EOL planning for AI systems must start at contracting and specifically account for model dependencies beyond vendor control, embedded data destruction, and the clinical revalidation requirements that make AI transitions substantially more complex than traditional software decommissioning.
In conclusion, the HSCC guide recognizes that the healthcare sector’s rapid AI adoption demands a fundamental shift in managing third-party technology risk. Traditional vendor risk practices fail to address AI systems that learn, drift, and rely on opaque supply chains. The guide provides a structured, lifecycle-based framework for healthcare organizations to mitigate risks, ensuring AI delivers value without compromising patient safety, data privacy, or operational continuity.
